Neoadjuvant celmiplimab is associated with pathologic response in cutaneous squamous cell carcinoma
1. After neoadjuvant treatment with celmiplimab, half of the patients were found to have a...
Read More
Oncology
Impact of ultrasonographic blind spots for early-stage hepatocellular carcinoma during surveillance
1. Hepatocellular carcinoma (HCC) tumours located in ultrasound (US) blind spots were associated...
Read More
Combination avelumab and axitinib treatment of advanced type B3 thymoma and thymic carcinoma is promising as second-line treatment after standard therapy.
1. Patients who had never previously received anti-angiogenesis treatments had longer...
Read More
Treatment with adjuvant mFOLFIRINOX as compared with gemcitabine improves survival outcomes in resected pancreatic cancer
1. Median disease-free survival is longer in patients receiving mFOLFIRINOX as compared to those...
Read More
Routine dexamethasone is not effective compared to placebo to treat dyspnea in patients with advanced cancer
1. There is no significant difference for perceived dyspnea in patients taking dexamethasone as...
Read More
Telaglenastat addition to cabozantinib did not demonstrate benefit in pre-treated advanced renal cell carcinoma
1. Telaglenastat addition to cabozantinib did not show improvements in clinical benefit. 2....
Read More
Incidence of C. difficile infections decreasing in hospitalized children
1. In a very large retrospective cohort of hospitalized pediatric patients, the incidence of C....
Read More
Adjuvant erlotinib increased overall survival when compared to chemotherapy in stage IIIA EGFR-mutant non-small cell lung cancer
1. Erlotinib showed an overall survival benefit and improved 5-year survival rates when compared...
Read More
Sacituzumab govitecan may be an effective treatment for heavily pre-treated HR+/HER2- metastatic breast cancer.
1. Median progression-free survival was longer in the SG group than in the chemotherapy group. 2....
Read More
Many Older Adults With Blood Cancer Taking Too Many Medications
Evaluating specific types of medications an older patient with blood cancer is taking is more...
Read More
Supervised exercise Interventions may significantly benefit childhood cancer survivors
1. Supervised exercise interventions significantly improved muscle strength, daily physical...
Read More
Criteria for low-dose computed tomography lung cancer screening omit a high risk population of smokers
1. A high risk of incident lung cancer exists for smokers that do not meet low-dose computed...
Read More
Same appointment mammogram results may result in less stress for patients being screened for breast cancer
1. Same appointment mammogram results had a positive impact on breast cancer screening experience...
Read More
Pembrolizumab plus chemotherapy improved survival in a subgroup of triple-negative metastatic breast cancer
1. Pembrolizumab plus chemotherapy for triple-negative breast cancer significantly increased PFS...
Read More
Topical hypericin photodynamic therapy is effective and safe in early-stage T cell lymphoma
1. Hypericin photodynamic therapy was found to be more efficacious in treating early-stage T cell...
Read More
Survival is similar for patients with autoimmune disease treated with immune checkpoint inhibitors compared to patients with no autoimmune disease
1. There was no significant difference in efficacy of ICIs in cancer patients with or without AID....
Read More
Breast, colorectal, and cervical cancer screening was reduced during the COVID-19 pandemic as compared to pre-COVID time periods.
1. All cancer types had the greatest decrease in screening during the early part of the pandemic....
Read More
LCAR-B38M CAR-T cell therapy promising at 4-year follow-up for treatment of refractory multiple myeloma
1. At a 4-year follow-up for relapsed or refractory multiple myeloma (RRMM) patients treated with...
Read More
IsoPSA Shows Notable Diagnostic Accuracy in Detecting Prostate Cancer
The IsoPSA biomarker displays superior diagnostic accuracy in the early detection of prostate...
Read More
FOLFOX combined with nivolumab and trastuzumab in ERBB2-positive esophagogastric adenocarcinoma is an emerging therapy option
1. Overall survival rate at 12 months for the FOLFOX arm and ipilimumab arm was 70% and 57%,...
Read More